Elevated serum growth differentiation factor 15 in multiple system atrophy patients:A case control study

作     者：Tao Yue Hui Lu Xiao-Mei Yao Xia Du Ling-Ling Wang Dan-Dan Guo Yi-Ming Liu 

作者机构：Department of NeurologyQilu HospitalCheeloo College of MedicineShandong UniversityJinan 250012Shandong ProvinceChina Department of GerontologyZibo Central HospitalZibo 255036Shandong ProvinceChina Department of OphthalmologyZibo Central HospitalZibo 255036Shandong ProvinceChina Department of GerontologyJinan Central HospitalCheeloo College of MedicineShandong UniversityJinan 250013Shandong ProvinceChina Department of NeurologyJinan Central Hospital Affiliated to Shandong UniversityJinan 250013Shandong ProvinceChina Department of NeurologyYantaishan HospitalYantai 264001Shandong ProvinceChina 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2020年第8卷第12期

页      面：2473-2483页

核心收录：

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

基　　金：Supported by National Natural Science Foundation of China,No.81771373 Key Research and Development Plan of Zibo City,No.2019ZC010169 and No.2019ZC010166 

主　　题：Multiple system atrophy Parkinson’s disease Serum growth differentiation factor 15 Biomarker Receiver-operating characteristic curve Neurodegenerative disease 

摘      要：BACKGROUND Multiple system atrophy(MSA) is a serious progressive neurodegenerative disease. Early diagnosis of MSA is very difficult, and diagnostic biomarkers are limited. Growth differentiation factor 15(GDF15) is involved in the differentiation and progression of the central nervous system, and is widely distributed in peripheral blood, which may be a novel biomarker for *** To determine serum GDF15 levels, related factors and their potential diagnostic value in MSA patients, compared with Parkinson’s disease(PD) patients and healthy *** A case-control study was conducted, including 49 MSA patients, 50 PD patients and 50 healthy controls. Serum GDF15 levels were measured by human enzymelinked immunosorbent assay, and the differences between the MSA, PD and control groups were analyzed. Further investigations were performed in different MSA subgroups according to age of onset, sex, clinical subtypes, diagnostic criteria, and disease duration. Receiver-operating characteristic curve analysiswas used to evaluate the diagnostic value of GDF15, especially for the differential diagnosis between MSA and *** Serum GDF15 levels were significantly higher in MSA patients than in PD patients and healthy controls(P = 0.000). Males and those with a disease duration of more than three years showed higher serum GDF15 levels(P = 0.043 and 0.000;respectively). Serum GDF15 levels may be a potential diagnostic biomarker for MSA patients compared with healthy controls and PD patients(cutoff: 470.42 pg/m L, sensitivity: 85.7%, specificity: 88.0%;cutoff: 1075.91 pg/m L, sensitivity:51.0%, specificity: 96.0%;respectively).CONCLUSION Serum GDF15 levels are significantly higher in MSA patients and provide suggestions on the etiology of MSA.